Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2016 Sep;57(9):1354-62.
doi: 10.1111/epi.13460. Epub 2016 Jul 4.

WONOEP appraisal: Molecular and cellular biomarkers for epilepsy

Lauren E Walker  1 , Damir Janigro  2 , Uwe Heinemann  3 , Raili Riikonen  4 , Christophe Bernard  5 , Manisha Patel  6
Affiliations
Review

WONOEP appraisal: Molecular and cellular biomarkers for epilepsy

Lauren E Walker et al. Epilepsia. 2016 Sep.

Abstract

Peripheral biomarkers have myriad potential uses for treatment, prediction, prognostication, and pharmacovigilance in epilepsy. To date, no single peripheral biomarker has demonstrated proven effectiveness, although multiple candidates are in development. In this review, we discuss the major areas of focus including inflammation, blood-brain barrier dysfunction, redox alterations, metabolism, hormones and growth factors.

Keywords: Blood-brain barrier; High mobility group box 1 (HMGB1); Inflammation; Insulin-like growth factor; S100B; brain derived neurotrophic factor.

PubMed Disclaimer

Conflict of interest statement

Disclosure of Conflicts of Interest

DJ holds a patent for the use of S100B in traumatic brain injury and stroke. MP is a consultant for Aeolus Pharma, which is developing catalytic antioxidants for human diseases. The remaining authors have no conflicts of interest. We confirm that we have read the Journal’s position on issues involved in ethical publication and affirm that this report is consistent with those guidelines.

Figures

Figure 1
Figure 1
The field of epilepsy biomarker discovery is wide, covering prediction, prognostication, and pharmacovigilance. Candidate biomarkers may span multiple areas or have relevance to restricted processes only.
Figure 2
Figure 2
Biomarkers are relevant to the whole developmental pipeline for new drug candidates.
See this image and copyright information in PMC

References

    1. Hulka B. Overview of biological markers. In: Hulka BS, Ja G, Hulka Barbara S, Wilcosky Timothy C, Griffith Jack D, editors. Biological markers in epidemiology. New York: Oxford University Press; 1990. pp. 3–15.
    1. Biomarkers Definitions Working G. Biomarkers and surrogate endpoints: preferred definitions and conceptual framework. Clin Pharmacol Ther. 2001;69:89–95. - PubMed
    1. Marchi N, Granata T, Janigro D. Inflammatory pathways of seizure disorders. Trends Neurosci. 2014;37:55–65. - PMC - PubMed
    1. Janigro D. Are you in or out? Leukocyte, ion, and neurotransmitter permeability across the epileptic blood-brain barrier. Epilepsia. 2012;53(Suppl 1):26–34. - PMC - PubMed
    1. Marchi N, Granata T, Freri E, et al. Efficacy of anti-inflammatory therapy in a model of acute seizures and in a population of pediatric drug resistant epileptics. PLoS ONE. 2011;6:e18200. - PMC - PubMed

Publication types

MeSH terms

Substances